SubjectsSubjects(version: 850)
Course, academic year 2019/2020
   Login via CAS
Hematology and Oncology - CVSE3P0010
Title in English: Hematologie a onkologie
Guaranteed by: Department of internal haematology (12-IHK)
Faculty: Third Faculty of Medicine
Actual: from 2018
Semester: summer
Points: 9
E-Credits: 9
Examination process: summer s.:
Hours per week, examination: summer s.:38/86 C+Ex [hours/semester]
Extent per academic year: 124 [hours]
Capacity: unknown / unknown (unknown)
Min. number of students: unlimited
State of the course: taught
Language: Czech, English
Teaching methods: full-time
Level:  
Guarantor: prof. MUDr. Tomáš Kozák, Ph.D.
Examination dates   Schedule   
Annotation -
Last update: prof. MUDr. Tomáš Kozák, Ph.D. (06.01.2016)
In Haematology and Oncology course students learn basics of epidemiology, pathogenesis, diagnostics, staging and therapy of both solid tumours and hematological malignancies as well as non-malignant hematological disorders. Theoretical introduction in form of lectures, that provides an overview of crucial topics in the subject, are followed by seminars that provide more detailed insight into respective diseases, their taxonomy, special pathology, diagnostics, clinical course and treatment. During the seminars on non-malignant hematology students learn basics of hematology laboratory practice, both morphology and coagulation part, with laboratory results inerpretation and basics of rational hemotherapy (transfusiology). At the practical lectures students are examining patients with particular malignant diseases. Haematooncological part of practical lectures are focused on case studies with differential diagnosis and treatment. The access to patients with haematological malignancies is limited because of deep immunosupression in most of them, but whenever it is possible, patients with clear signs of haematological disease, especially with lymphadenopathy and splenomegaly, are demonstrated to the students. In the oncological and haematooncological part of the course students learn basics of therapy of tumorous diseases according to the evidence based medicine, innovation in biological therapy and basics of modern supportive and paliative care. Preventive care and early diagnosis principals of both malignant and non- malignant haematologic diseases will be also mentioned.
Aim of the course -
Last update: prof. MUDr. Tomáš Kozák, Ph.D. (10.02.2012)

The aim of the subject will be to give students basic knowledge of management of neoplasias and also non malignant diaseases of blood. Students will be introduced to epidemiology, clinical signs, staging and basdics of treatment of soild tumors as well as non-malignant hematology disorders. The course will also enable to gain practical skills in communication with an oncology patient.

Literature -
Last update: prof. MUDr. Tomáš Kozák, Ph.D. (22.09.2019)

Haematology part:

Hoffbrand V.A., Moss P.A.H: Hoffbrand´s Essential Haematology, 7. edition, Wiley Blackwell,  2015

 

Teaching methods -
Last update: prof. MUDr. Tomáš Kozák, Ph.D. (10.02.2012)

Lectures, seminars, practice at the respective department 

Requirements to the exam -
Last update: prof. MUDr. Tomáš Kozák, Ph.D. (22.09.2019)
For the school year 2019/20120 apply following rules for getting credits and passing exams:
 
Credits will be given to students who participated in at least 60% of semminars and practical lessons and succeeded in the written test containing 15 questions. Credit will be given during last week of the practical training, Final exam will follow, it will be oral with 3 questions to be answered (1 haematology or haematooncology, 1 oncology, 1 priciples of (hemato)oncology care including special pharmacology). To by eligible for final oral exam the student must have passed the exam from General Foundations of Pathology and Pathophysiology (CVSE3P0011). Terms for final exams will be posted in time in SIS (EXAM DATES) 
 
 

 

Topics/questions  HEMONK for oral exam 3. year, general medicine

 

Topics & Questions – Oncology School year 2019/2020

  1. Cancerogenesis
  2. Staging and disease response assesment
  3. Hormonal therapy in oncology
  4. Chemoterapy - mode of action
  5. Chemotherapy - side effects
  6. Immunotherapy in oncology
  7. Targeted therapy in solid tumor oncology
  8. Prevention a screeining in oncology
  9. Emergency situation in oncology
  10. Principles of radiotherapy in oncology
  11. Radiotherapy- side effects
  12. Palliative therapy in oncology
  13. Supportive care in oncology
  14. Pain and its therapy in oncology
  15. Malignant tumours in oncology
  16. Malignant tumours of oropharynx
  17. Malignant tumours of larynx
  18. Breast carcinoma
  19. Malignant tunmours of lungs
  20. Malignant tumour of stomach nad oesophagus
  21. Malignant tumours of pancreas and liver
  22. Colorectal carcinoma
  23. Malignant tumours of the skin
  24. Ovarial malignant tumours
  25. Malignant tumours of corpus uteri
  26. Malignant tumours of cervix uteri
  27. Prostate cancer
  28. Malignant tumours of kidneys 
  29. Urinary bladder malignant tumours
  30. Testicular malignant tumours
  31. Soft tissue sarcoma
  32. Anal carcinoma

 

 

Questions – Hematology for school year 2018/2019

1.       Laboratory examination in haematology

2.       Morfological classification of anaemia

3.       Iron defficiency anaemia

4.       Pernicious anaemia

5.       AIHA

6.       TTP/HUS

7.       Thalassemia and sicle cell disease

8.       PNH

9.       Hereditary spherocytosis and  G-6-P-D deficiency

10.   Aplastic anaemia

11.   Neutrophilia and its causes

12.   Neutropenia and its causes

13.   Eosinophilia and its causes

14.   Lymphocytosis and its causes

15.   Thrombocytopenia: causes and 

16.   ITP

17.   Thrombocytosis and its causes

18.   Thrombocytopathy

19.   Acute myeloid leukaemia (AML)

20.   Acute lymphoblastic leukaemia (ALL)

21.   Chronic myelogenous leukaemia (CML)

22.   Primary (idiopathic) myelofibrosis (PMF)

23.   Polycythaemia vera

24.   Essential thrombocytaemia (ET)

25.   Chronic lymphocytic leukaemia (CLL)

26.   Lymphoma classification and staging

27.   Hodgkin's lymphoma (HL)

28.   Diffuse large B cell lymphoma (DLBCL)

29.   Mantle cell lymphoma (MCL)

30.   Follicular lymphoma (FL)

31.   Burkitt's lymphoma (BL)

32.   Marginal zone lymphoma (MZL)

33.   Waldenström's macroglobulinaemia

34.    T- cell lymphoma 

35.   MGUS

36.   Multiple myeloma

37.   Alkylating agents, antimetabolites and topoisomerase inhibitors in the treatment of neoplastic diseases  F

38.   Anthracyclins, platinating agents, nukleoside analogs in the treatment of neoplastic diseases  F

39.   Corticosteroids in the treatment of neoplastic diseases F

40.   Targetted („biological“) therapy in hematooncology F

41.   Supportive care in hematooncology, treatment of pain F

42.   Hemophilia

43.   Von Willebrand's disease

44.   Anticoagulation treatment. Heparin, Warfarin and new oral anticoagulants F

45.   Antiaggregation treatment F

46.   DIC

47.   Thrombosis a thrombophilia

48.   Antiphospholipid syndrome, lupus anticoagulans

49.   Blood products, indication for transfusion and complications

50.   Blood derivatives, indication to administration, complications

 

 

Syllabus -
Last update: prof. MUDr. Tomáš Kozák, Ph.D. (22.09.2019)

Syllabus HEMONK 2019/2020

  

 
Charles University | Information system of Charles University | http://www.cuni.cz/UKEN-329.html